INTRODUCTION
Lung cancer is the main cause of cancer death worldwide, and smoking is the major risk factor. Usually diagnosed at an advanced stage, lung cancer is the most common malignancy in China, with the highest mortality rate in male malignancies and the second highest mortality rate in female malignancies.
Angiogenesis has an important role in tumor progression and metastasis, and vascular endothelial growth factor (VEGF) is a key element in this pathological process. VEGF, located on chromosome 6p21.3 with eight exons and seven introns, is a regulator of vascular endothelium that promotes vascular growth, which eventually leads to proliferation and metastasis of tumor cells. 1 Accumulating data have shown that VEGF affects clinical outcomes of a wide range of cancers, including but not limiting to esophageal cancer, breast cancer, colon cancer, renal cancer, liver cancer and urinary bladder cancer. [2] [3] [4] Genetic instability such as gene replication, deletion and mutation is a hallmark of tumors. Genome-wide association studies suggest that single-nucleotide polymorphism (SNP) affects pathogenesis of different kinds of human cancers. VEGF polymorphisms may influence VEGF synthesis. And several VEGF SNPs have been recently identified. Among them, − 460 T/C SNP (rs833061) is located in the promoter region and +405G/C SNP (rs2010963) is located within the 5′-untranslated region. These two SNPs have been found to be associated with various cancers, including lung cancer. 5 Recently, Renner et al. 6 found that mutation of 936C → T in VEGF gene can eliminate binding site of the transcription activator protein-4 (AP-4), which results in three-times lower level of plasma VEGF and consequent decreased risk of breast cancer. Recent studies also identified in lung cancer a spectrum of VEGF gene polymorphisms such as 257 8 A/C, 405G/C and 936C/T. 7 However, little is known about the significance of VEGF gene polymorphisms in the development of lung cancer in a Chinese population. The present study was to investigate whether VEGF − 460 and +405 SNPs affect risk of lung cancer, and the results demonstrated that C allele of +405G/C in VEGF gene was associated with increased risk of lung cancer in males and carrying GCTC haplotype was associated with this risk in general population.
MATERIALS AND METHODS Patients
This study was carried out in accordance with the approved guidelines by the Ethics Committee of the Fourth Hospital of Hebei Medical University and patients have signed an informed consent. From September 2008 to October 2011, a total of 260 patients with pathologically confirmed lung cancer and 260 healthy individuals were enrolled in this study at the Department of Thoracic Surgery, the Fourth Affiliated Hospital of Hebei Medical University (Table 1) . None of the patients had received preoperative radiotherapy or chemotherapy, nor did any of them have vascular proliferative conditions or concomitant cancers. The 260 healthy volunteers were Han Chinese without any kinship with the patients. Information about age, sex and smoking history was collected from the patients with lung cancer and the healthy individuals.
PCR
The genotype analysis of +405G/C, − 460 T/C, − 1154G/A, − 2578C/A polymorphism of VEGF gene was done by polymerase chain reactionbased restriction fragment length polymorphism and primer introduced restriction analysis-PCR. To extract blood mononuclear cell DNA, peripheral blood mononuclear cells were isolated from the blood samples of patients and total DNAs were isolated using proteinase K digestion-salting method. The four genetic loci were listed as follows: (1) VEGF-1154G/A:
The primers used were: (1) S1-F: 5′-GGCGGATGGGTAATTTTCAGG-3′; S1-R: 5′-TCCCCGCTACCAGCCGACTTT-3′, 236 bp; (2) S2-F: 5′-CCTAGCACCTC CACCAAACCA-3′; S2-R: 5′-CAGGGAACAAAGTTGGGGCTC-3′, 233 bp; (3) S3-F: 5′-TGAATGG AGCGAGCAGCGTCT-3′; S3-R: 5′-CGTGCGGACAGGGCC TGAGA-3′, 236 bp; (4) S4-F: 5′-TGTGGATTTTGGAAACCAGCAGA-3′; S4-R: 5′-CGGTGTCTGTCTGTCTGTCCG-3′, 234 bp.
The PCR was carried out in 15-μl volume, containing 1 μl of DNA template, 1.5 μl of the PCR buffer, 1.25 units of Taq DNA polymerase, 25 nM of each primer, 3 mM of deoxynucleotide triphosphate and 2.5 mM of MgCl2. The amplification was done with 94°C, 2 min; 55°C, 15 s, 72°C, 25 s, 72°C, 3 min, 35 cycles.
Restriction analysis
The following probes were used: S1-TA: 5′-GCCCGGGCCCGAGCCGCGTG TGGAA-3′; S1-TG: 5′-TTTGCCCGGGCCCGAGCCGCGTGTGGAG-3′; S1-TR: 5′-P-GGGCTGAGGCTCGCCTGTCCCCGCC-FAM-3′; S2-TA: 5′-TTTTCCAGCTGT AGGCCAGACCCTGGCAA-3′; S2-TC: 5′-TTTTTTTCCAGCTGTAGGCCAGACCCT GGCAC-3′; S2-TR: 5′-P-GATCTGGGTGGATAATCAGACTGACTTT-FAM-3′; S3-TC: 5′-TTTTTTTTAGTGTGTGCGTGTGGGGTTGAGGGC-3′; S3-T T: 5′-TTTTTTTTTTTA GTGTGTGCGTGTGGGGTTGAGGGT-3′; S3-TR: 5′-P-GTTGGAGCGGGGAGAAGG CCAGGGGTTTTTT-FAM-3′; S4-TC: 5′-TTTTTTTTTTTTGCGCGGGCGTGCGAGCAG CGAAAGC-3′; S4-TG: 5′-TTTTTTTTTTTTTTTGCGCGGGCGTGCGAGCAGCGAAA GG-3′; S4-TR: 5′-P-GACAGGGGCAAAGTGAGTGACCTGCTTTTTTTTT-FAM-3′.
The ligation reaction was performed in 10-μl volume, containing 3 μl of PCR product, 1.0 μl of Taq DNA ligase buffer, 5 units of Taq DNA ligase, 0.1 pmol of each probe. The ligation reaction was done at 94°C, 30 s followed by 56°C, 1 min, 25 cycles. The sizes of the ligation products were: S1: 50/A, 53/G; S2: 57/A, 60/C; S3: 64/C, 67/T; S4: 71/C, 74/G.
Sequencing
Sequencing of 1 μl of the ligation products was done with ABI 3730XL DNA analyzer.
Statistical analysis
Statistical analysis was done with SPSS 13.0 version. Correlation of VEGF gene polymorphism with risk of lung cancer was analyzed with logistic regression. Haplotype and gene linkage analysis was conducted with SHSsis. Po 0.05 was considered statistically significant.
RESULTS
First of all, SNP genotypes of+405G / C, − 460 T / C, − 1154G / A, − 2578C/A were consistent with Hardy-Weinberg equilibrium in both healthy control and patient subjects in this study (χ 2 = 0.760, P = 0.384, χ 2 = 1.554, P = 0.213; χ 2 = 0.502, P = 0.479 and χ 2 = 1.488, P = 0.223, respectively), which indicated a representative distribution of the subjects in the regional population.
As showed in Table 1 , no significant difference of gender distribution and age ratio existed between lung cancer patients and the healthy individuals (Tables 1, P40.05). As expected, positive smoking history was higher in the patient group than that in healthy volunteers. Also, prevalence of lung cancer is higher in males than that in females.
Genotype analysis results demonstrated that, VEGF − 460T/C, − 1154G/A, − 2578C/A SNPs did not increase the risk of development of lung cancer (Table 2) . However, in patients with lung Lung cancer patients n = 414 (%) Controls n = 338 (%)
P-value
Lung cancer patients n = 295 (%) Controls n = 184 (%)
Lung cancer patients n = 119 (%) Controls n = 154 (%) cancer, the C allele genotype (G/C and C/C) of VEGF +405G/C SNP, although not correlating with histopathological type of the tumor, was significantly associated with increase of risk of lung cancer in females, comparing that of G/G genotype (P o 0.05, (Table 4) . Stratified statistical analysis also showed that, compared with that of G/G genotype, C allele genotype-associated increase in risk of lung cancer was neither histological-type specific nor gender related (Table 3 , Figures 1, 2, 3 ). Restriction fragment length polymorphism analysis also demonstrated that polymorphism of 460 T/C, − 1154G/A, − 2578C/A alleles was not correlated with risk of development of lung cancer regardless of pathological type of the tumor, after adjustment against age, sex, smoking status (P-value all 40.05).
More interesting, our data of haplotype analysis of VEGF − 460 T/C and VEGF 405G/C polymorphism loci demonstrated that part linkage disequilibrium between the polymorphic loci (D′ = 0.56, P = 0.00) (Figure 4) . Compared with that of VEGF405G/ 460 T haplotype, VEGF405G/460C haplotype significantly increased the risk of lung cancer (odds ratio = 1.32, 95% confidence interval = 1.08~1.96).
DISCUSSION
Lung cancer is a leading cause of cancer mortality and disease burden worldwide, with the vast majority of lung cancers present as advanced on diagnosis. 8 Various risk factors for development of lung cancer have been identified, including exposure to physical (radon), chemical (smoking, cooking oil fumes and indoor coal burning) and biological (human papillomavirus, Mycobacterium tuberculosis) carcinogens. 9 Recent studies have shown that genetic instability also contributes to the development of lung cancer (Table 5 ). For example, positive family history is an independent risk for this tumor, and recent studies have identified SNP polymorphisms in individual genes or micro RNAs associated with increased risk for this malignancy. [10] [11] [12] [13] [14] [15] [16] In the present study, we found that VEGF +405G/C SNP polymorphism is associated with risk of lung cancer. Consistent with results of previous clinical and experimental studies, our data also indicated that smoking is a risk factor for lung cancer, with a predilection in males.
VEGF is a key mediator of angiogenesis by binding membrane receptors whose intra-cytoplasm tic domain presents tyrosine kinase activity. [17] [18] [19] VEGF and its receptors are frequently overexpressed in human tumors and inhibition of angiogenesis with bevacizumab, a monoclonal antibody that selectively binds to VEGF has shown promising clinical efficacy. [20] [21] [22] [23] [24] Multiple studies have shown that high VEGF expression in tumor or in serum is an indicator of prognosis of non-small cell lung cancer and response to anti-angiogenesis. 25, 26 As such, VEGF SNP has been extensively investigated for its role in predicting cancer susceptibility, progression and anti-VEGF therapeutic response in subjects with tumors. Numerous SNPs in the promoter, 5′-, and 3′-untranslated regions in VEGF gene have been identified. Interestingly, 634G4C SNP in the 5′-untranslated regions and 936C4T SNP in the 3′-untranslated regions of VEGF gene affect tumor tissue expression of VEGF.
Several threads of evidence give diverse picture of VEGF SNP in lung cancer. Koukourakis et al. reported in a 36-case study that − 2578 CC, − 634 GG and − 1154 AA and GA genotypes are associated with low VEGF expression, whereas − 2578 CA, − 634 GC and − 1154 GG genotypes do the opposite. In the 1900-case NSCLC study, -634G4C increases and − 1498 T/ − 634G/936C haplotype reduces the risk of lung cancer in Caucasian males, respectively. 27, 28 This phenomenon disappears after adjusting for age, gender, smoking status, pack-years of smoking and years since smoking cessation. Yet Heist et al. 29 found that carriers of -634C and 936 T alleles had longer 5-year overall survival than non carriers. In contrast, in the present study, we found that VEGF +405G/C SNP, but not the other three SNPs (−460 T/C, − 1154G/A, − 2578C/A) were associated with the increased risk of lung cancer in male Han Chinese individuals, especially in the smokers. And our haplotype analysis demonstrated that part linkage disequilibrium between the VEGF − 460 T/C and VEGF − 405G/C polymorphic loci and VEGF405G/460C haplotype significantly increased the risk of lung cancer. Taken together, VEGF SNP is a significant genetic factor associated with the development of lung cancer.
Although emerging data indicate that VEGF SNP has an important role in the development, invasion and prognosis of lung cancer, more questions about this phenomenon are needed to be answered. VEGF polymorphism, susceptibility of lung cancer C Liu et al
